FDA approves Impax's Rytary for Parkinson's

Impax Laboratories Inc. (NASDAQ:IPXL) jumped $3.61 (12%) to $34.60 on Thursday after FDA approved the company's Rytary extended release carbidopa/levodopa to treat Parkinson's disease (PD). Spokesperson Mark Donohue said Impax plans to launch the drug in 2Q15 but has not yet decided on a price.

The oral combination of carbidopa and levodopa contains both immediate-release and extended-release beads. The drug is contraindicated in patients taking a nonselective monoamine oxidase (MAO) inhibitor, as concurrent use can cause hypertension. ...